2. Search Result
Search Result
Results for "

MCI

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

5

Isotope-Labeled Compounds

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101693A
    Senazodan hydrochloride

    MCI 154 hydrochloride

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Senazodan (MCI 154) (hydrochloride), as a Ca 2+ sensitiser, shows inhibition effect on PDE III .
    Senazodan hydrochloride
  • HY-112939
    Colestilan

    MCI-196; Colestimide

    		 Biochemical Assay Reagents Metabolic Disease
    Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research .
    Colestilan
  • HY-B1558A
    Bifemelane hydrochloride
    1 Publications Verification

    MCI-2016

    		 Monoamine Oxidase Neurological Disease
    Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease .
    Bifemelane hydrochloride
  • HY-10564
    Sarpogrelate hydrochloride
    1 Publications Verification

    MCI-9042

    		 5-HT Receptor Cardiovascular Disease
    Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .
    Sarpogrelate hydrochloride
  • HY-155031
    MCI

    		Reactive Oxygen Species (ROS) COX Inflammation/Immunology Cancer
    MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC50 value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA) .
    MCI
  • HY-124905
    MCI-176

    		Calcium Channel Cardiovascular Disease
    MCI-176 is a calcium antagonist. MCI-176 competitively inhibits calcium-induced constriction of coronary arteries .
    MCI-176
  • HY-U00247
    MCI826

    		P-glycoprotein Cancer
    MCI826 is a P-glycoprotein (P-gp) antagonist.
    MCI826
  • HY-101693
    Senazodan

    MCI 154

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Senazodan (MCI 154) is a Ca 2+ sensitiser, and also shows inhibition effect on PDE III .
    Senazodan
  • HY-123498
    MCI-225 (dehydratase)

    DDP 225 (dehydratase)

    		 5-HT Receptor Adrenergic Receptor Neurological Disease
    MCI-225 dehydratase is an orally active and selective noradrenaline reuptake inhibitor. MCI-225 dehydratase also is a 5-HT3 antagonist and shows antidepressant effects in vivo .
    MCI-225 (dehydratase)
  • HY-10563
    Sarpogrelate

    MCI-9042 free acid

    		 5-HT Receptor Infection
    Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease .
    Sarpogrelate
  • HY-10564S1
    Sarpogrelate-d4 hydrochloride

    MCI-9042-d4

    		 Isotope-Labeled Compounds 5-HT Receptor Cardiovascular Disease
    Sarpogrelate-d4 (MCI-9042-d4) hydrochloride is deuterium labeled Sarpogrelate (hydrochloride). Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .
    Sarpogrelate-d4 hydrochloride
  • HY-169884
    MCI-INI-3

    		Aldehyde Dehydrogenase (ALDH) Cancer
    MCI-INI-3 is a selective competitive inhibitor of human ALDH1A3 (with a Ki value of 0.55 μM for ALDH1A3 and a Ki value of 78.2 μM for ALDH1A1). MCIINI-3 inhibits the biosynthesis of retinoic acid and reduces the viability of GSC-83 and GSC-326 glioblastoma cells .
    MCI-INI-3
  • HY-10564R
    Sarpogrelate hydrochloride (Standard)

    MCI-9042 (Standard)

    		 Reference Standards 5-HT Receptor Cardiovascular Disease
    Sarpogrelate (hydrochloride) (Standard) is the analytical standard of Sarpogrelate (hydrochloride). This product is intended for research and analytical applications. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .
    Sarpogrelate hydrochloride (Standard)
  • HY-10564S
    Sarpogrelate-d3 hydrochloride

    MCI-9042-d3

    		 Isotope-Labeled Compounds 5-HT Receptor Cardiovascular Disease
    Sarpogrelate-d3 (hydrochloride) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .
    Sarpogrelate-d3 hydrochloride
  • HY-B0099
    Edaravone
    Maximum Cited Publications
    29 Publications Verification

    MCI-186

    		 MMP Apoptosis Neurological Disease
    Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
    Edaravone
  • HY-B1558
    Bifemelane

    MCI-2016 free base

    		 Calcium Channel Neurological Disease
    Bifemelane is a nootropic compound. Bifemelan causes the first peak by stimulating release from intracellular Ca 2+ stores and the second by capacitive entry through store–operated Ca 2+ channels. Bifemelane will be provided as a pharmacological tool for basic studies on astrocytes .
    Bifemelane
  • HY-B0099R
    Edaravone (Standard)

    MCI-186 (Standard)

    		 Reference Standards MMP Apoptosis Neurological Disease
    Edaravone (Standard) is the analytical standard of Edaravone. This product is intended for research and analytical applications. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
    Edaravone (Standard)
  • HY-B0375A
    Argatroban monohydrate
    5 Publications Verification

    MD-805 monohydrate; MCI-9038 monohydrate; Argipidine monohydrate

    		 Thrombin Cardiovascular Disease Cancer
    Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.
    Argatroban monohydrate
  • HY-RS08229
    MCIDAS Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MCIDAS Human Pre-designed siRNA Set A contains three designed siRNAs for MCIDAS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MCIDAS Human Pre-designed siRNA Set A
    MCIDAS Human Pre-designed siRNA Set A
  • HY-B0099S
    Edaravone-d5

    MCI-186-d5

    		 Isotope-Labeled Compounds MMP Apoptosis Neurological Disease
    Edaravone-d5 is a deuterium labeled Edaravone. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator .
    Edaravone-d5
  • HY-B0375AR
    Argatroban monohydrate (Standard)

    MD-805 monohydrate (Standard); MCI-9038 monohydrate (Standard); Argipidine monohydrate (Standard)

    		 Reference Standards Thrombin Cardiovascular Disease Cancer
    Argatroban (monohydrate) (Standard) is the analytical standard of Argatroban (monohydrate). This product is intended for research and analytical applications. Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.
    Argatroban monohydrate (Standard)
  • HY-B0375S1
    Argatroban-13C6 hydrochloride

    MD-805-13C6 hydrochloride; MCI-9038-13C6 hydrochloride; Argipidine-13C6 hydrochloride

    		 Thrombin Isotope-Labeled Compounds Cardiovascular Disease
    Argatroban- 13C6 hydrochloride is 13C labeled Argatroban (HY-B0375). Argatroban (MD-805) is a direct, selective thrombin inhibitor.
    Argatroban-13C6 hydrochloride
  • HY-101481
    Flurbiprofen axetil

    		COX Apoptosis MEK ERK PPAR AMPK NF-κB Interleukin Related TNF Receptor STAT Wnt Neurological Disease Inflammation/Immunology Cancer
    Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway .
    Flurbiprofen axetil
  • HY-101481R
    Flurbiprofen axetil (Standard)

    		Reference Standards COX Apoptosis MEK ERK PPAR AMPK NF-κB Interleukin Related TNF Receptor STAT Wnt Neurological Disease Inflammation/Immunology Cancer
    Flurbiprofen axetil (Standard) is the analytical standard of Flurbiprofen axetil. This product is intended for research and analytical applications. Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway .
    Flurbiprofen axetil (Standard)
  • HY-10933
    CX516
    2 Publications Verification

    BDP 12

    		 iGluR Neurological Disease
    CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .
    CX516
  • HY-10933S
    CX516-d10

    BDP 12-d10

    		 Isotope-Labeled Compounds iGluR Neurological Disease
    CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .
    CX516-d10
  • HY-173481
    CDK9-IN-37

    		CDK Cancer
    CDK9-IN-37 (Compound 24) is a CDK9 inhibitor (EC50: 5.5 nM) with weak inhibition on other CDK isoforms, showing high selectivity. CDK9-IN-37 has significant antiproliferative activity against acute myeloid leukemia MOLM-13 cells (IC50: 0.034 μM). CDK9-IN-37 inhibits the CDK9 signaling pathway, reduces the phosphorylation level of RNAP II CTD (Ser2), downregulates the anti-apoptotic protein McI-1, induces cell apoptosis, and arrests the cell cycle at the G2/M phase. CDK9-IN-37 can be used in the study of acute myeloid leukemia (AML) .
    CDK9-IN-37
  • HY-132806
    Alogabat

    RG-7816; RO-7017773

    		 GABA Receptor Neurological Disease
    Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
    Alogabat
  • HY-17550
    Sunifiram

    DM-235

    		 iGluR Neurological Disease
    Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .
    Sunifiram
  • HY-17550R
    Sunifiram (Standard)

    DM-235 (Standard)

    		 Reference Standards iGluR Neurological Disease
    Sunifiram (Standard) is the analytical standard of Sunifiram. This product is intended for research and analytical applications. Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .
    Sunifiram (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: